News Feed Item

Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register


Insmed Incorporated Analyst Notes

On February 19, 2014, Insmed Incorporated (Insmed) provided an interim update from its CLEAR-110 study-- an ongoing life-threatening, open-label extension study of once-daily ARIKACE® to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients. The Company informed that the data showed patients taking ARIKACE actually saw their FEV (Forced Expiratory Volume) levels remain above baseline on average, and also experienced a sustained reduction in density of Pa sputum while on treatment. Commenting on the study results, Will Lewis, President and CEO of Insmed, stated, "With the results achieved in our Phase 3 trial, along with these positive interim data, we continue our preparation for regulatory filings with the European Medicines Agency and Health Canada, which remain on target for mid-year." The full analyst notes on Insmed Incorporated are available to download free of charge at:



Medtronic, Inc. Analyst Notes

On February 26, 2014, Medtronic, Inc.'s (Medtronic) stock went up by 0.63%, closing at $57.81. After opening at $57.63, the stock oscillated in a range of $57.52-$58.22, with total volume of 4.00 million. For the past three day trading period, Medtronic shares went up by 1.21%, compared to the Dow Jones Industrial Average which gained 0.59% during the same period. The full analyst notes on Medtronic, Inc. are available to download free of charge at:



CR Bard Inc. Analyst Notes

On February 26, 2014, CR Bard Inc.'s (CR Bard) stock went up by 0.76%, ending the day at $143.04. The stock opened at $142.04, and traded in a range of $141.68-$144.06 during the session. Over the past three day trading period, the Company's stock went up by 1.04%, compared to the S&P 500 which advanced 0.49% during the same period. The full analyst notes on CR Bard Inc. are available to download free of charge at:



Laboratory Corp. of America Holdings Analyst Notes

On February 24, 2014, Laboratory Corp. of America Holdings (LabCorp) announced that an agreement has been entered into with Thermo Fisher Scientific, Inc (Thermo Fisher), under which the Company gets access to latter's Thermo Scientific ImmunoCAP™ allergy testing portfolio of more than 600 allergens and 100 allergen components. Commenting on the agreement, Dr. Mark Brecher, LabCorp's Chief Medical Officer, stated, "LabCorp offers an extensive test menu which supports a diagnosis of allergy and, just as importantly, can assist in ruling out allergies as a source of symptoms and thereby suggest other etiologies. We will continue to offer a comprehensive range of tests for regional allergies, food allergies, oral allergy syndrome, pediatric allergens and workplace allergy exposures, and we will develop customized panels to improve treatment practices and enhance patient outcomes." The full analyst notes on Laboratory Corp. of America Holdings are available to download free of charge at:



Acceleron Pharma, Inc. Analyst Notes

On February 26, 2014, Acceleron Pharma, Inc. (Acceleron) reported its Q4 2013 and full year 2013 financial results. Collaboration revenue of Acceleron went up to $11.5 million in the quarter and to $57.2 million in full year 2013, compared to $4.0 million in Q4 2012 and $15.3 million in full year 2012.

For the quarter, net loss applicable to common shareholders was $18.1 million, or $0.64 per diluted share, compared to net loss applicable to common shareholders of $17.1 million, or $7.10 per diluted share, in Q4 2012. Full year 2013 net loss applicable to common shareholders was $39.0 million, or $4.15 per diluted share, compared to net loss applicable to common shareholders of $59.6 million, or $24.84 per diluted share, in full year 2012. Acceleron stated that Q4 2013 and full year 2013 results were affected by the expenses associated with marking to market outstanding warrants to purchase of common stock. The full analyst notes on Acceleron Pharma, Inc. are available to download free of charge at:



About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.




  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...
Digital Transformation and Disruption, Amazon Style - What You Can Learn. Chris Kocher is a co-founder of Grey Heron, a management and strategic marketing consulting firm. He has 25+ years in both strategic and hands-on operating experience helping executives and investors build revenues and shareholder value. He has consulted with over 130 companies on innovating with new business models, product strategies and monetization. Chris has held management positions at HP and Symantec in addition to ...
Cloud-enabled transformation has evolved from cost saving measure to business innovation strategy -- one that combines the cloud with cognitive capabilities to drive market disruption. Learn how you can achieve the insight and agility you need to gain a competitive advantage. Industry-acclaimed CTO and cloud expert, Shankar Kalyana presents. Only the most exceptional IBMers are appointed with the rare distinction of IBM Fellow, the highest technical honor in the company. Shankar has also receive...
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
Daniel Jones is CTO of EngineerBetter, helping enterprises deliver value faster. Previously he was an IT consultant, indie video games developer, head of web development in the finance sector, and an award-winning martial artist. Continuous Delivery makes it possible to exploit findings of cognitive psychology and neuroscience to increase the productivity and happiness of our teams.
There is a huge demand for responsive, real-time mobile and web experiences, but current architectural patterns do not easily accommodate applications that respond to events in real time. Common solutions using message queues or HTTP long-polling quickly lead to resiliency, scalability and development velocity challenges. In his session at 21st Cloud Expo, Ryland Degnan, a Senior Software Engineer on the Netflix Edge Platform team, will discuss how by leveraging a reactive stream-based protocol,...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities - ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups.
The standardization of container runtimes and images has sparked the creation of an almost overwhelming number of new open source projects that build on and otherwise work with these specifications. Of course, there's Kubernetes, which orchestrates and manages collections of containers. It was one of the first and best-known examples of projects that make containers truly useful for production use. However, more recently, the container ecosystem has truly exploded. A service mesh like Istio addr...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
Predicting the future has never been more challenging - not because of the lack of data but because of the flood of ungoverned and risk laden information. Microsoft states that 2.5 exabytes of data are created every day. Expectations and reliance on data are being pushed to the limits, as demands around hybrid options continue to grow.
Business professionals no longer wonder if they'll migrate to the cloud; it's now a matter of when. The cloud environment has proved to be a major force in transitioning to an agile business model that enables quick decisions and fast implementation that solidify customer relationships. And when the cloud is combined with the power of cognitive computing, it drives innovation and transformation that achieves astounding competitive advantage.
Poor data quality and analytics drive down business value. In fact, Gartner estimated that the average financial impact of poor data quality on organizations is $9.7 million per year. But bad data is much more than a cost center. By eroding trust in information, analytics and the business decisions based on these, it is a serious impediment to digital transformation.
Digital Transformation: Preparing Cloud & IoT Security for the Age of Artificial Intelligence. As automation and artificial intelligence (AI) power solution development and delivery, many businesses need to build backend cloud capabilities. Well-poised organizations, marketing smart devices with AI and BlockChain capabilities prepare to refine compliance and regulatory capabilities in 2018. Volumes of health, financial, technical and privacy data, along with tightening compliance requirements by...
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
"NetApp is known as a data management leader but we do a lot more than just data management on-prem with the data centers of our customers. We're also big in the hybrid cloud," explained Wes Talbert, Principal Architect at NetApp, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.